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sFlt1–Soluble fms-like Tyrosine Kinase 1 
HELLP–Hemolysis, Elevated Liver Enzymes, and Low Platelet count 
VEGF–Vascular Endothelial Growth Factor  
PlGF–Placental Growth Factor  
BMI–Body Mass Index  
CNS–Central Nervous System  




Preeclampsia is a relatively common complication of pregnancy. 
Occurring in 7% of all pregnancies in the US, it is defined as an in-
crease in blood pressure combined with proteinuria. More severe 
cases of preeclampsia have the potential to advance into eclampsia, 
which is preeclampsia with the addition of seizures. Preeclampsia 
and eclampsia have the ability to cause lasting harm or death to 
both mother and fetus, but the cause of these diseases is largely 
unclear (Papadakis & McPhee, 2017).
Risk factors for preeclampsia are known. Hypertension, kidney 
disease, family history, diabetes, and obesity are all linked to a high-
er incidence of preeclampsia. Preeclampsia is commonly called a 
disease of the first pregnancy, though women who have had pre-
eclampsia before are also at greater risk of developing it in sub-
sequent pregnancy. Strangely enough, cigarette smoking seems to 
prevent preeclampsia. There are other known risk factors as well.
Some of the pathophysiology of preeclampsia is understood. 
It is believed that preeclampsia develops from poor placenta-
tion and the release of soluble fms-like tyrosine kinase 1 (sFlt1) 
into the mother’s bloodstream. However, the increase in sFlt1 
levels is often not distinct enough to use as a screening tool. 
Additionally, the original cause of the increase is unknown.
Treatment of preeclampsia is largely based on symptoms, with 
the goal being the continuation of the pregnancy for as long 
as possible. Almost all symptoms disappear within 48 hours 
after delivery, so it is in the mother’s best interest to give birth. 
Conversely, the fetus needs more time in utero to develop. The 
physician must balance the conflicting needs of the two patients 
by managing the mother’s symptoms. Further understanding of 
the underlying causes of preeclampsia can result in more effec-
tive treatment and better outcomes for preeclamptic women 
and their children.
Methods
Peer-reviewed journal articles were obtained using Touro 
College’s database and Google Scholar. The articles were criti-
cally read, analyzed, and compared. Special attention was given 
to retrospective studies and reviews due to the dearth of origi-
nal studies in their references. This can be attributed to the fact 




Preeclampsia is a complication of pregnancy involving hyperten-
sion and proteinuria. It cannot be prevented. Instead, pregnant 
women are screened for symptoms and treated accordingly. 
These symptoms usually present in the third trimester, but can 
occur from 20 weeks’ gestation. It is diagnosed when a patient 
presents with blood pressure of 140/90 or greater, and more 
than 0.3 g of proteinuria in 24 hours. Some women also have 
edema. Severe preeclampsia involves higher blood pressure 
as well as thrombocytopenia, headache, and blurred vision 
(Papadakis & McPhee, 2017). 
Severe preeclampsia is also characterized by hemolysis, ele-
vated liver enzymes, and low platelet count (HELLP) syndrome. 
This diagnosis was first made in 1982 and is currently found 
in 0.2-0.8% of pregnancies. HELLP syndrome is rarely seen in 
non-preeclamptic patients, though preeclampsia is about ten 
times as common as HELLP. Like preeclampsia, HELLP is a syn-
drome, a collection of symptoms whose one underlying cause is 
uncertain. The hemolysis aspect is a result of damaged endothe-
lial cells in small blood vessels. Fibrin strands in the blood ves-
sels cause red blood cells to become fragmented, often causing 
anemia. Microangiopathy also slows hepatic portal blood flow, 
damaging the liver. The same microangiopathy also exposes 
tissue factor on blood vessel walls which activates coagulation 
pathways. These blood clots lower platelet counts and can lead 
to further complications such as uncontrolled bleeding or pla-
cental abruption (Abildgaard & Heimdal, 2013). 
If preeclampsia continues, it can develop into eclampsia, which 
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is defined as all of the symptoms of preeclampsia with the addi-
tion of seizures. Eclampsia is easily prevented by administration 
of magnesium, so it is usually only seen in patients lacking pre-
natal care, or in developing countries where access to this anti-
convulsant is unavailable. Hyperexcitability and extreme reflex 
responses are typical signs that eclampsia may be developing 
(Papadakis & McPhee, 2017; Duley, 2009).
Preeclampsia is primarily a disease of the mother, so the fetus is 
not always affected. This is especially true in milder cases of pre-
eclampsia, where the pregnancy is allowed to continue until term. 
However, this is not to say that the fetus is never endangered. 
Fetal growth restriction is a complication often correlated with 
preeclampsia. Because of the mother’s angiopathy, blood supply to 
the fetus can be reduced. This does not allow the fetus to receive 
adequate nutrition, causing a low birth weight (Duley, 2009).
More seriously, preeclampsia often forces an early delivery be-
cause of the mother’s symptoms. Preterm delivery, in this case 
meaning before 34 weeks’ gestation, is associated with various 
complications. There is the immediate problem of insufficient 
surfactant maturity in the lungs, causing the baby to go into respi-
ratory distress upon birth. Low birth weight often causes com-
plications later in life, including cardiovascular problems, diabetes, 
and obesity. Additionally, increased risk of cerebral palsy has been 
associated with children of preeclamptic mothers. Although pre-
eclampsia primarily affects the mother, the fetus is not spared of 
all effects (Papadakis & McPhee, 2017; Duley, 2009).
Causes of Preeclampsia
The causes of preeclampsia are poorly understood. Because 
preeclampsia is a syndrome, a collection of symptoms which 
may or may not come from one underlying cause, the pathogen-
esis can be different for different patients. Most people agree 
that preeclampsia’s cause lies in the placenta due to the fact 
that the disease disappears upon delivery. It is hypothesized 
that poor placentation is a cause of preeclampsia. In normal 
pregnancies, cytotrophoblasts from the placenta invade the 
mother’s myometrium and increase blood supply to the fetus. In 
preeclamptic placentas, insufficient invasion and remodeling of 
the mother’s arteries occur. The placenta is therefore hypoxic, 
and parts of it break down and release debris into maternal 
circulation. This debris, containing trophoblast cells and keratin 
fragments, causes the inflammatory response of preeclampsia, 
microangiopathy and hypertension (Redman & Sargent, 2005).
Normal placentas release vascular endothelial growth factor 
(VEGF) and placental growth factor (PlGF). Both are angiogenic 
factors which allow the placenta to build an adequate vascular 
network for the fetus’s development. When VEGF or PlGF binds 
to a receptor on placental cell surfaces, increased vascularity is 
shown. A soluble form of this receptor, soluble fms-like tyrosine 
kinase-1 (sFlt1), increases in the third trimester. This receptor 
floats freely in the placenta and maternal serum. When sFlt1 
binds to VEGF or PlGF, they are unable to create blood vessels, 
proving sFlt1 to be antiangiogenic, and possibly the cause of 
the poor placentation described above. This factor is further 
increased in preeclampsia, and is found to increase even before 
clinical signs of the syndrome are evident. It is believed that 
excess sFlt1 can cause preeclampsia; what is unknown is how 
this excess develops in the first place and what can be done to 
prevent it (Redman & Sargent, 2005; Levine et al., 2004).
It is believed that decreased free VEGF and PlGF in the ma-
ternal blood supply leads to the endothelial dysfunction of pre-
eclampsia. In the kidneys, the lack of free VEGF causes glomer-
ular endotheliosis; constantly circulating VEGF is necessary for 
renal function. The swelling of kidney cells then does not allow 
for proper filtration of the blood, causing proteinuria. Exactly 
how or if sFlt1 causes hypertension is unknown.
As would be expected, women with lower VEGF and PlGF lev-
els and higher sFlt1 levels tend to have more severe symptoms 
of preeclampsia and eclampsia. Additionally, when sFlt1 is adminis-
tered to nonpregnant rats, they develop preeclamptic symptoms. 
VEGF inhibitors or VEGF gene knockouts cause hypertension and 
proteinuria in pregnant and nonpregnant rats. Cancer patients 
taking VEGF-inhibitors to limit blood supply to a tumor will also 
often exhibit hypertension and proteinuria, further proving the 
role of sFlt1 in preeclampsia (Levine et al., 2004).
Preeclampsia is widely considered a disease of the nullipa-
rous woman. In a Norwegian study examining data from over 
700,000 births between 1967 and 1998, preeclampsia was found 
in 3.9% of first pregnancies (Skjærven et al., 2002). This is com-
pared to a 1.7% incidence for second pregnancies, and 1.8% for 
third. The incongruous increase for third pregnancies is quite 
small and probably a statistical artifact. It is unknown exactly 
why preeclampsia is much more common in first pregnancies. 
What is known is that if a mother was preeclamptic in her first 
pregnancy, she is at risk for preeclampsia in later pregnancies 
as well. Somehow, nulliparity seems to cause preeclampsia. This 
Norwegian study claims that preeclampsia is a result of the 
mother being exposed to her partner’s foreign antigens and 
responding inflammatorily, causing preeclampsia. In later preg-
nancies by the same man, preeclampsia is less likely because 
the partner’s antigens are no longer unrecognized by her body. 
Giving weight to this theory, the more time that elapsed be-
tween pregnancies, the more likely the mother was to develop 
preeclampsia, even if she had not previously been preeclamp-
tic. As time passed, the immune system’s ability to recognize a 
partner’s antigens decreased. Women whose second pregnan-
cies were by different partners appear to have the same risk of 
preeclampsia as nulliparous women. This supports the idea that 
preeclampsia is partially caused by foreign antigens; a new part-
ner supplies new antigens for which the mother is unprepared. 
However, since women who have changed partners often have a 
larger birth interval, it is very uncertain if the change in partner 
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actually increases the risk for preeclampsia. Interestingly, pre-
vious miscarriage seems to reduce the risk of preeclampsia in 
a later, successful pregnancy. This can also be connected to the 
idea of interbirth interval, as many women who miscarry at-
tempt to get pregnant again very soon thereafter. Nulliparity is 
known to be a risk factor for preeclampsia; the reason for this is 
not totally clear (Skjærven et al., 2002; Sibai et al., 1995).
Risk Factors
There are many risk factors for preeclampsia, including chronic 
hypertension and kidney dysfunction, obesity, diabetes, previous 
preeclamptic pregnancies, family history of the mother or father, 
birth interval, age of the mother, as well as other preexisting 
conditions. This paper will analyze some of the more credible 
risk factors and attempt to explain the connection between 
them and the disease. 
Nulliparity is the most known risk factor for preeclampsia. 
Whether this is due to an immune response or some other 
mechanism is largely unknown. What is known is that nullipa-
rous women are more than three times more likely to develop 
preeclampsia than women who have previously had normoten-
sive pregnancies (Duckitt & Harrington, 2005).
Women with chronic hypertension unrelated to their 
pregnancy are known to have a higher risk of developing pre-
eclampsia and eclampsia. In one population-based study, 12.1% 
of preeclamptic women were found to have had hypertension 
before they became pregnant (Duckitt & Harrington, 2005). This 
is quite logical; high blood pressure before becoming pregnant 
leads to even higher blood pressure while pregnant. Clinically, 
blood pressure is used to diagnose preeclampsia. Preeclampsia 
is defined as systolic blood pressure of 140 mmHg or greater 
and/or diastolic blood pressure of 90 mmHg or greater, and at 
least 300 mg of proteinuria over 24 hours. Blood pressure can 
also be used to screen for preeclampsia. Elevated blood pres-
sure is normal in pregnancy, but too high an elevation can be a 
sign that preeclampsia will develop. In one study of nearly 3000 
women, the mean systolic blood pressure at 20 weeks gestation 
was 105.4 for healthy pregnancies, and 110.4 for those who 
later developed preeclampsia. This is a substantial difference, but 
clinically it would be difficult to gain any benefit from this sta-
tistic. Diastolic and mean blood pressure were not as useful for 
prediction. Not surprisingly, women who displayed significantly 
elevated blood pressure at 20 weeks were more likely to devel-
op preeclampsia earlier than those whose blood pressure was 
not as elevated. This is a more useful diagnostic tool. Systolic 
blood pressure of 110 as opposed to 105 is hardly grounds to 
begin watching more closely for preeclampsia. Systolic blood 
pressure of 125 or 130 is (Sibai et al., 1995).
As with hypertension, kidney dysfunction before pregnancy 
is likely to lead to increased kidney dysfunction while preg-
nant, i.e. preeclampsia. Less research has been done on kidney 
dysfunction leading to preeclampsia, though. In one study of 69 
pregnancies, 6.7% of women with recurring urinary tract in-
fections developed preeclampsia, and only 2.6% of the control 
group did. In other words, 2 of the 39 women with renal dis-
ease developed preeclampsia, and only 1 healthy woman did. 
This is hardly enough evidence on which to build a treatment 
plan. Logically, the connection between renal disease and pre-
eclampsia seems just as strong as that between hypertension 
and preeclampsia. However, not nearly as much research was 
done on this juxtaposition, perhaps because of the relative rar-
ity of renal disease in women of childbearing age (Duckitt & 
Harrington, 2005).
Non-gestational diabetes greatly increases the risk of pre-
eclampsia. A meta-analysis of multiple studies with a total 
count of 56,968 women revealed that the risk of developing 
preeclampsia is 3.56% greater for women who have diabetes 
before pregnancy. These studies are often connected to studies 
linking preeclampsia and obesity, which also approximately qua-
druples the risk of preeclampsia. Because women with diabetes 
and high BMI often have other health problems, it is difficult 
to assess exactly which of their characteristics make them 
more likely to develop preeclampsia (Sibai et al., 1995; Duckitt 
& Harrington, 2005). In a Saudi Arabian study of the effects of 
obesity and gestational diabetes on pregnancy, it was found that 
approximately 7% of women with obesity and/or gestational di-
abetes develop preeclampsia, compared to only 0.5% of women 
with neither. The combination of the two seems to increase the 
risk (Wahabi et al., 2014).
The connection between obesity and preeclampsia has been 
linked to inflammation. Obesity is inflammatory, as is preeclamp-
sia, so it stands to reason that one inflammatory state can cause 
the development of an inflammatory disease. Additionally, pre-
eclampsia often develops from hypoxic conditions in the pla-
centa. Obesity can encourage this. Obesity is often linked with 
hyperglycemia, causing hemoglobin to pick up glucose and lose 
its affinity for oxygen. This does not allow enough oxygen to 
reach the placenta, leading to an inflammatory response, the 
release of cytokines, and subsequent endothelial dysfunction of 
preeclampsia (Redman & Sargent, 2005; Schmatz et al., 2010).
Previously having preeclampsia puts a woman up to seven 
times at risk for developing the disease in subsequent pregnan-
cies when compared to women who have never had preeclamp-
sia. It is assumed that whatever caused her to be susceptible in 
the first place will also cause later incidences of preeclampsia. 
A family history also puts a woman more at risk, though the 
mother-in-law’s pregnancies do not seem to have much of an 
effect (Sibai et al., 1995; Duckitt & Harrington, 2005).
Treatment
Treatment options for preeclampsia are largely based on symp-
toms. The best treatment is delivery, but immediate delivery is 
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not always an option. Other treatments therefore are based on 
prolonging the pregnancy for as long as possible, keeping the 
mother’s health in mind (Papadakis & McPhee, 2017).
When systolic blood pressure rises above 160 mmHg, or di-
astolic above 110, antihypertensive drugs are administered to 
bring blood pressure back down to 140/90, the threshold for 
preeclampsia’s diagnosis. In severe preeclampsia, steps are taken 
to ensure that the patient will not develop eclampsia. If the 
mother begins to experience muscle spasms or hyperexcitabili-
ty, showing that her CNS is beginning to be affected, magnesium 
sulfate is administered as a relaxant. Magnesium is also given to 
patients with eclampsia. Obviously, these women are monitored 
for toxicity. Calcium has been suggested as an aid in preeclamp-
sia, but no real benefits have been proven (Papadakis & McPhee, 
2017; Levine et al., 2004).
Delivery is the best option for the mother, and it is the treat-
ment of choice from 36 weeks onward. Before that point, clini-
cians must decide if the fetus is ready for life outside the womb. 
If the fetus’s lungs are not mature enough for birth, corticoste-
roids are administered to the mother for 48 hours, followed 
by induced delivery or cesarean. The steroids allow the fetus’s 
lungs to mature more quickly. If the mother’s symptoms are 
severe, such as in eclampsia, waiting for fetal lung maturation is 
not necessarily an option. Delivery must then be induced to the 
detriment of the fetus (Papadakis & McPhee, 2017).
Preeclampsia is a major cause of preterm delivery. Early de-
livery is often necessary for the mother’s sake; the child suffers. 
Premature birth can result in respiratory distress, admittance to 
the NICU, low birth weight, jaundice, seizures, as well as other 
complications in infancy and later in life (Papadakis & McPhee, 
2017). Fetal mortality is a large concern; preeclampsia is cor-
related with 25% of stillbirths and neonatal deaths in developing 
countries (Duley, 2009).
Both aspirin and nicotine appear to reduce the risk of pre-
eclampsia. Aspirin has antihypertensive properties, so its role in 
decreasing the incidence of preeclampsia makes sense. In one 
study of healthy, nulliparous women, 4.6% of those given aspirin 
developed preeclampsia, compared to 6.9% of those given place-
bo. However, the aspirin did increase the risk of abruptio placen-
tae, which makes the idea of treating all pregnant women with 
aspirin less appealing (Sibai et al., 1993). It is recommended by 
some for women at high risk for preeclampsia (Sibai et al., 1995).
Cigarette smoking is known to decrease the risk of pre-
eclampsia, but doctors are hardly likely to begin advising smok-
ing during pregnancy. One explanation for this phenomenon is 
that nicotine appears to play a role in reducing the amount of 
sFlt1 in the mother’s bloodstream. This ameliorates preeclamp-
sia’s antiangiogenic effects and does not allow inflammation to 
cause the mother to develop hypertension and proteinuria. 
Even if smokers develop preeclampsia, it is usually not very se-
vere. In a clinical trial testing aspirin’s effect, 5.9% of nonsmokers 
developed preeclampsia, compared to 2.7% of those who quit 
during pregnancy, and 3.7% of those who smoked throughout. 
The many negative effects of cigarette smoking on both mother 
and child, though, far outweigh the small shielding from pre-
eclampsia’s effects (Sibai et al., 1993; Jeyabalan et al., 2008).
The current treatments for preeclampsia are less than ideal, 
but experimental treatments may give us some better options. 
It is important to note that designing preclinical and clinical tri-
als for these treatments can be quite difficult. Animal models are 
often less than ideal as these animals may have very different 
placentas than humans. Many of these trials involve animals that 
do not ever develop preeclampsia. Scientists instead create situ-
ations to mimic preeclampsia’s symptoms in vivo. Moving on to 
a clinical trial in humans will only occur after extensive testing. 
Nobody wants a repeat of the thalidomide disaster, so advance-
ment in pregnancy treatment moves slowly (Sibley, 2017).
In a 2016 study of 28 rats, apelin was used to successfully 
ameliorate symptoms of preeclampsia. Apelin is a peptide found 
in the cardiovascular system. Among other effects, it reduces 
blood pressure in atherosclerosis and encourages angiogene-
sis. In this experiment, half of the rats served as control (N 
group), and half of these were given apelin (N+APLN group), 
an angiogenic factor naturally present in mammalian placentas. 
Preeclamptic placentas usually have lower apelin than normal. 
The acceptable rat model of preeclampsia was used on half the 
rats (PE and PE+APLN); uterine arteries were clamped to pre-
vent adequate blood flow to the placenta, leading to the release 
of cytokines and debris causing hypertension and proteinuria. 
Half of these rats were then treated with apelin. The rats given 
apelin had lower blood pressure and proteinuria than the pre-
eclamptic control, but not as low as the healthy rats. Apelin also 
increased fetal survival rate and birth weight. One hundred per-
cent of N and N+APLN embryos survived, 25% of PE survived, 
and 50% of PE+APLN survived. Considering that fetal survival 
rate for humans with preeclampsia is much better than 25%, 
it is reasonable to believe that apelin would cause even better 
survival rates in humans. The effect on preeclampsia’s maternal 
symptoms are also likely to carry over. However, as apelin was 
only tested on 8 preeclamptic rats, and because rat placentas 
differ greatly from human ones, much more research must be 
done before apelin is the drug of choice for preeclampsia (Sibley, 
2017; Wang et al., 2017).
Researchers have also recommended mediating the effect of 
sFlt1 on the mother’s body by somehow increasing the levels of 
VEGF in the placenta. One method of doing so is by injecting 
adenovirus vectors for VEGF into the placenta. This was done 
in sheep and guinea pig models, as well as in human placentas 
in vitro. The increase in VEGF levels mediates the inactivation 
of VEGF by sFlt1, resulting in an approximately normal quanti-
ty of angiogenic factors. This appears to create normal uterine 
blood flow and cure preeclampsia. The virus vector also does 
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not appear to cross the placenta and cause other complications. 
This treatment is extremely promising and is moving towards 
clinical trial in Europe (Sibley, 2017).
Conclusion
Preeclampsia is a major obstetrical complication still common 
in the developed world. Its causes are not fully understood, but 
are largely believed to develop from hypoxic conditions of the 
placenta. The placenta releases inflammatory factors, causing hy-
pertension and proteinuria for the mother, as well as other side 
effects. Fetal effects include growth restriction and the negative 
effects related to premature birth. Risk factors are well-known 
yet poorly understood, and prophylactic treatments such as 
aspirin are available. Treatment for preeclampsia and eclampsia 
now mainly revolve around symptoms, but experiments are un-
derway which will hopefully lead to a greater understanding and 
more effective treatment for this syndrome.
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